Chemistry

Conjugate vaccine produces long-lasting attenuation of fentanyl vs. meals alternative and blocks expression of opioid withdrawal-induced will increase in fentanyl alternative in rats


1.

Protect BCB 2018. https://www.bcbs.com/the-health-of-america/stories/the-opioid-epidemic-america-update.

2.

Hedegaard H, Warner M, Minino AM Drug Overdose Deaths in america, 1999–2016. NCHS Information Temporary. 2017:1–eight.

three.

Volkow ND, Frieden TR, Hyde PS, Cha SS. Medicine-assisted therapies — tackling the opioid-overdose epidemic. New Engl J Med. 2014;370:2063–66.

four.

Volkow ND, Woodcock J, Compton WM, Throckmorton DC, Skolnick P, Hertz S. et al. Medicine growth in opioid dependancy: Significant scientific finish factors. Sci Transl Med. 2018;10:eaan2595.

5.

Volkow ND, Collins FS. The function of science in addressing the opioid disaster. New Engl J Med. 2017;377:391–94.

6.

Banks ML, Olson ME, Janda KD. Immunopharmacotherapies for treating opioid use dysfunction. Traits Pharmacol Sci. 2018;39:908–11.

7.

Baehr C, Pravetoni M. Vaccines to deal with opioid use problems and to cut back opioid overdoses. Neuropsychopharmacology. 2019;44:217–18.

eight.

Bremer PT, Janda KD. Conjugate vaccine immunotherapy for substance use dysfunction. Pharmacol Rev. 2017;69:298–315.

9.

Hwang CS, Bremer PT, Wenthur CJ, Ho SO, Chiang S, Ellis B, et al. Enhancing efficacy and stability of an antiheroin vaccine: examination of antinociception, opioid binding profile, and lethality. Mol Pharm. 2018;15:1062–72.

10.

Sulima A, Jalah R, Antoline JFG, Torres OB, Imler GH, Deschamps JR, et al. A secure heroin analogue that may function a vaccine hapten to induce antibodies that block the results of heroin and its metabolites in rodents and that cross-react immunologically with associated medication of abuse. J Med Chem. 2018;61:329–43.

11.

Bremer PT, Schlosburg JE, Banks ML, Steele FF, Zhou B, Poklis JL, et al. Growth of a clinically viable heroin vaccine. J Am Chem Soc. 2017;139:8601–11.

12.

Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR. Modifications in heroin self-administration by a rhesus monkey after morphine immunisation. Nature. 1974;252:708–10.

13.

Schlosburg JE, Vendruscolo LF, Bremer PT, Lockner JW, Wade CL, Nunes AAK, et al. Dynamic vaccine blocks relapse to compulsive consumption of heroin. Proc Natl Acad Sci USA. 2013;110:9036–41.

14.

Nguyen JD, Hwang CS, Grant Y, Janda KD, Taffe MA. Prophylactic vaccination protects in opposition to the event of oxycodone self-administration. Neuropharmacology. 2018;138:292–303.

15.

Pravetoni M, Pentel PR, Potter DN, Chartoff EH, Tally L, LeSage MG. Results of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced mind gene expression in rats. PLOS ONE. 2014;9:e101807.

16.

Banks ML, Negus SS. Insights from preclinical alternative fashions on treating drug dependancy. Traits Pharm Sci. 2017;38:181–94.

17.

Epstein DH, Heilig M, Shaham Y. Science-based actions may also help tackle the opioid disaster. Traits Pharmacol Sci. 2018;39:911–16.

18.

Banks ML. Utility of preclinical drug versus meals alternative procedures to guage candidate medicines for methamphetamine use dysfunction. Ann New Y Acad Sci. 2017;1394:92–105.

19.

Banks ML, Hutsell BA, Schwienteck KL, Negus SS. Use of preclinical drug vs. meals alternative procedures to guage candidate medicines for cocaine dependancy. Curr Deal with Choices. Psychiatry. 2015;2:136–50.

20.

Negus SS, Banks ML. Medicines Growth for Opioid Abuse. In: Pierce RC, Kenny PJ, editors. Dependancy. New York: Chilly Springs Harbor; 2013.

21.

Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological results of heroin. Psychopharmacology. 2006;189:37–46.

22.

Tanum L, Solli Ok, Latif Z, et al. Effectiveness of injectable extended-release naltrexone vs day by day buprenorphine-naloxone for opioid dependence: a randomized scientific noninferiority trial. JAMA Psychiatry. 2017;74:1197–205.

23.

Mantsch JR, Baker DA, Funk D, Le AD, Shaham Y. Stress-induced reinstatement of drug searching for: 20 years of progress. Neuropsychopharmacology. 2016;41:335–56.

24.

Kowalczyk WJ, Phillips KA, Jobes ML, Kennedy AP, Ghitza UE, Agage DA, et al. Clonidine upkeep prolongs opioid abstinence and decouples stress from craving in day by day life: a randomized managed trial with ecological momentary evaluation. Am J Psychiatry. 2015;172:760–7.

25.

Kowalczyk WJ, Bertz JW, Moran LM, Phillips KA, Ghitza UE, Epstein DH, et al. Clonidine will increase the probability that abstinence can stand up to unstructured time in buprenorphine-maintained outpatients. J Addict Med. 2017;11:454–60.

26.

Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. A multi-center randomized trial of buprenorphine–naloxone versus clonidine for opioid, detoxing: findings from the Nationwide Institute on Drug Abuse Medical Trials Community. Dependancy. 2005;100:1090–100.

27.

Wade CL, Vendruscolo LF, Schlosburg JE, Hernandez DO, Koob GF. Compulsive-like responding for opioid analgesics in rats with prolonged entry. Neuropsychopharmacology. 2015;40:421–28.

28.

Wurster RM, Griffiths RR, Findley JD, Brady JV. Discount of heroin self-administration in baboons by manipulation of behavioral and pharmacological situations. Pharmacol Biochem Behav. 1977;7:519–28.

29.

Lenoir M, Cantin L, Vanhille N, Serre F, Ahmed SH. Prolonged heroin entry will increase heroin selections over a potent nondrug different. Neuropsychopharmacology. 2013;38:1209–20.

30.

Negus SS, Banks ML. Modulation of drug alternative by prolonged drug entry and withdrawal in rhesus monkeys: implications for unfavourable reinforcement as a driver of dependancy and goal for medicines growth. Pharmacol Biochem Behav. 2018;164:32–39.

31.

Negus SS. Alternative between heroin and meals in nondependent and heroin-dependent rhesus monkeys: results of naloxone, buprenorphine, and methadone. J Pharm Exp Ther. 2006;317:711–23.

32.

Negus SS, Rice KC. Mechanisms of withdrawal-associated will increase in heroin self-administration: pharmacologic modulation of heroin vs meals alternative in heroin-dependent rhesus monkeys. Neuropsychopharmacology. 2009;34:899–911.

33.

Huskinson SL, Naylor JE, Townsend EA, Rowlett JK, Blough BE, Freeman KB. Self-administration and behavioral economics of second-generation artificial cathinones in male rats. Psychopharmacology. 2017;234:589–98.

34.

Townsend EA, Naylor JE, Negus SS, Edwards SR, Qureshi HN, McLendon HW, et al. Results of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant results of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacology. 2017;234:2597–605.

35.

Thomsen M, Barrett AC, Negus SS, Caine SB. Cocaine versus meals alternative process in rats: environmental manipulations and results of amphetamine. J Exp Anal Behav. 2013;99:211–33.

36.

Negus SS. Fast evaluation of alternative between cocaine and meals in rhesus monkeys: results of environmental manipulations and remedy with d-Amphetamine and flupenthixol. Neuropsychopharmacology. 2003;28:919–31.

37.

Banks ML, Blough BE. Results of environmental maniuplations and bupropion and risperidone remedies on alternative between methamphetamine and meals in rhesus monkeys. Neuropsychoharmacology. 2015;40:2198–206.

38.

Ossipov MH, Harris S, Lloyd P, Messineo E, Lin BS, Bagley J. Antinociceptive interplay between opioids and medetomidine: systemic additivity and spinal synergy. Anesthesiology. 1990;73:1227–35.

39.

Bremer PT, Kimishima A, Schlosburg JE, Zhou B, Collins KC, Janda KD. Combatting artificial designer opioids: a conjugate vaccine ablates deadly doses of fentanyl class medication. Angew Chem Int Ed. 2016;55:3772–75.

40.

Maguire DR, Gerak LR, Woods JH, Husbands SM, Disney A, France CP. Lengthy-lasting results of methocinnamox on opioid self-administration in rhesus monkeys. J Pharmacol Exp Ther. 2019;368:88–99.

41.

Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the remedy of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210–18.

42.

Matthew L, Banks E, Andrew T, Negus SS. Testing the 10 most needed: a preclinical algorithm to display screen candidate opioid use dysfunction medicines. Neuropsychopharmacology. 2019;44:1011–12.

43.

Stowe GN, Vendruscolo LF, Edwards S, Schlosburg JE, Misra KK, Schulteis G, et al. A vaccine technique that induces protecting immunity in opposition to heroin. J Med Chem. 2011;54:5195–204.

44.

Raleigh MD, Pentel PR, LeSage MG. Pharmacokinetic correlates of the results of a heroin vaccine on heroin self-administration in rats. PLOS ONE. 2014;9:e115696.

45.

Affiliation AP. Diagnositc and Statistical Guide of Psychological Problems. Fifth Version. Arlington, VA: American Psychiatric Affiliation; 2013.

46.

Spragg SDS. Morphine Dependancy in Chimpanzees. Comparative Psychology Monographs. Baltimore, MD: The John Hopkins Press; 1940. p. 1–132.

47.

Hwang CS, Smith LC, Natori Y, Ellis B, Zhou B, Janda KD. Efficacious vaccine in opposition to heroin contaminated with fentanyl. ACS chemical. Neuroscience. 2018;9:1269–75.


Supply hyperlink
asubhan

wordpress autoblog

amazon autoblog

affiliate autoblog

wordpress web site

web site growth

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close